Neutralising antibody potency against SARS-CoV-2 wild-type and omicron BA.1 and BA.4/5 variants in patients with inflammatory bowel disease treated with infliximab and vedolizumab after three doses of COVID-19 vaccine (CLARITY IBD): an analysis of a prospective multicentre cohort study
Zhigang Liu, Kaixing Le, Xin Zhou, James L. Alexander et autres
36 citationsThe Lancet. Gastroenterology & hepatology